TBPH Q2 2018 Earnings — Theravance Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

TBPHTheravance Biopharma, Inc.

$697M

Q2 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$23M+569.0% YoY

Gross Profit

-$24M-100.9% margin

Operating Income

-$49M-207.5% margin

Net Income

-$41M-173.9% margin

EPS (Diluted)

$-0.76

QoQ Revenue Growth

+182.2%

Cash Flow

Operating Cash Flow

-$62M

Free Cash Flow

-$63M

Stock-Based Comp.

$14M

Balance Sheet

Total Assets

$421M

Total Liabilities

$387M

Stockholders' Equity

$34M

Cash & Equivalents

$104M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$23M	$4M	+569.0%
Gross Profit	-$24M	$2M	-1204.8%
Operating Income	-$49M	-$65M	+25.2%
Net Income	-$41M	-$66M	+38.4%

Revenue Segments

Collaborative Arrangement Revenue

$16,000100%